Complex Innovative Design
Decentralized Clinical Trials
European Medicines Agency
Hybrid Clinical Trials
In-Vitro Diagnostic Regulation
Outsourcing Clinical Trials
Real-World Evidence (RWE)
Research & Development
Research and Development
Robotic-Assisted Surgery (RAS)
RWE Decision Alert
Alira Health Secures an Additional $40M in Funding, Led by Creadev
We announced today the closing of an equity financing in which it raised gross proceeds of US$40 million. The financing was provided by key existing investors Creadev, an evergreen(...)
Alira Health Strengthens Growth Strategy with $35M Funding, led by Creadev
Alira Health strengthens its growth strategy with a $35M funding, led by Creadev.
We Announce our role as Strategic Advisor to Mérieux Equity Partners and Mérieux Participations 3 for Entering the Capital of CTRS
We are pleased to announce our role as strategic advisor to Mérieux Equity Partners as they join the Series A financing round of Cell-Easy, through Mérieux’s newly established venture fund, OMX.
Alira Health as Strategic Advisor to Benvic in Acquisition Luc & Bel
We are proud to announce our role as strategic advisor to Benvic in the acquisition of Luc & Bel.
We Announce our Role as Advisor to Sagard NewGen
We are pleased to announce our role as Advisor to Sagard NewGen for the equity investment in Laboratoires Delbert. This recent capital raise of €40m supports the company’s growth(...)
We Announce our Role as Exclusive Strategic Advisor to AGC Biologics in its Acquisition of MolMed SpA
We are proud to announce our role as strategic advisor to AGC Biologics, a leading global biopharmaceutical contract development, and manufacturing organization, in their acquisition(...)
We Announce our Role as a Transaction Advisor to Daiichi Sankyo on the Sale of LOPRESSOR®, ICAZ®, and MIOREL® to SIT Laboratorio Farmaceutico (DESMA HC Group)
Daiichi Sankyo France /(hereafter, Daiichi Sankyo) and SIT Laboratorio Farmaceutico (DESMA HC Group) are pleased to announce the acquisition of LOPRESSOR®, ICAZ® and MIOREL® by SIT(...)
Alira Health Welcomes Romain Finas, Vice President, Real-World Evidence
Alira Health is excited to welcome Romain Finas as our new Vice President, Real-World Evidence. Based in Paris, France, Romain brings deep expertise in real-world data, healthcare workflow(...)
Latest from Alira Health
The 2024 Global Medtech Contract Manufacturing Report: Executive Summary
The Importance of Involving Patients in the Health Technology Assessment Process for Rare Diseases
Experts Annabel de Maria and Ahmad Bechara share how engaging rare disease patients in the HTA process gives them the opportunity to have a meaningful impact.
Biopharma in 2024: The Industry Outlook
Insights from recent J.P. Morgan Healthcare Conference including what's changed in biopharma since last year and what to expect this year.
Pharma Company Succeeds in Adding Medicine to World Health Organization Essential Medicines List
A pharma company with a blood disorder treatment needed support to submit a value dossier to the WHO to add a medicine to the Essential Medicines List.
Pharma Company Extends to New Markets through Strategic Licensing Agreements
A Swedish pharma company saw a market opportunity to expand access to its proprietary product outside of the Nordics and sought support developing strategic licensing deals.
Pharma Develops e-Health Solution That Prioritizes Patients’ True Unmet Needs
A leading pharma company in the respiratory market sought support developing the right digital platform to expand their patient base and increase retention.
Connect with our biotech experts onsite in Barcelona at Bio-Europe Spring. How can we support your development plan and funding path?
XXII Conferenza Nazionale Sulla Farmaceutica
Meet Giovanni Firenze, Partner Consulting Italy, onsite in Catania and learn more about the impact of the new AIFA reform.
World EPA Congress Europe
Look for market access and pricing experts Ahmad Bechara and Andrea Mantovani representing Alira Health on the agenda at World EPA Congress.
Robotic-assisted Surgery in Orthopedic Procedures: Current Landscape and 2024 Outlook
What Comes After the mRNA Vaccines?
In the third episode of VacciTalks, we’ll discuss these new alternatives to mRNA vaccines and the promise they hold.
Medtech CDMO: Market and M&A Global Trends in 2024
This webinar replay investigates the current state of the global medtech CDMO industry and highlight Europe as a promising frontier for consolidation.
The 2024 Global Medtech Contract Manufacturing Report
Discover the trends in the world of medical device CDMOs and their meaning for the industry in 2024 and beyond.
FDA Approves GAMMAGARD LIQUID Based on Safety Data From an RWE Study
Food and Drug Administration (FDA) approves GAMMAGARD LIQUID based on safety data from a real-world evidence study.
UK HTA Recommends KANUMA in Pediatric Patients Based Partly on Comparative RWD
KANUMA underwent a recent appraisal by the UK's NICE for the treatment of Wolman disease in children aged two years and under.
Best Practices for Health Technology Assessment of Robotic Assisted Surgery
An expert panel developed seven best-practice recommendations for evaluating Robotics Assisted Surgical systems and here are the results.
Therapeutic IgG-Like Bispecific Antibodies: Modular Versatility and Manufacturing Challenges
Our experts conducted a deep evaluation of IgG-like bsAbs including general advantages and disadvantages compared with MAbs and more.
Immunoglobulin Fc-Fusion Proteins
Our experts published a series of articles in BioProcess International reviewing the state of the art of Fc – fusion proteins, including their structure and molecular design, manufacturing(...)